
OrthoPediatrics entered into an exclusive distribution agreement with OSSIO to provide U.S. children’s hospitals with bio-integrative, metal-free fixation technology for the treatment of fractures and deformities in pediatric patients.
OSSIOfiber implants are made from a proprietary blend of natural mineral fibers that provide initial fixation strength comparable to traditional metal implants while safely and completely integrating into the patient’s own bone tissue within 18–24 months post-implantation, leaving no hardware behind.
Joe Hauser, President of Trauma and Deformity at OrthoPediatrics, said, “OSSIOfiber implants reduce the rate of secondary procedures by doing away with metal. From a strategic perspective, partnering with OSSIO expands our reach and capabilities with a revolutionary technology that complements OrthoPediatrics’ current product offering, allowing us to address more unmet pediatric needs while strengthening the company’s long-term growth potential.”
Source: OrthoPediatrics Corp.
OrthoPediatrics entered into an exclusive distribution agreement with OSSIO to provide U.S. children’s hospitals with bio-integrative, metal-free fixation technology for the treatment of fractures and deformities in pediatric patients.
OSSIOfiber implants are made from a proprietary blend of natural mineral fibers that provide initial fixation...
OrthoPediatrics entered into an exclusive distribution agreement with OSSIO to provide U.S. children’s hospitals with bio-integrative, metal-free fixation technology for the treatment of fractures and deformities in pediatric patients.
OSSIOfiber implants are made from a proprietary blend of natural mineral fibers that provide initial fixation strength comparable to traditional metal implants while safely and completely integrating into the patient’s own bone tissue within 18–24 months post-implantation, leaving no hardware behind.
Joe Hauser, President of Trauma and Deformity at OrthoPediatrics, said, “OSSIOfiber implants reduce the rate of secondary procedures by doing away with metal. From a strategic perspective, partnering with OSSIO expands our reach and capabilities with a revolutionary technology that complements OrthoPediatrics’ current product offering, allowing us to address more unmet pediatric needs while strengthening the company’s long-term growth potential.”
Source: OrthoPediatrics Corp.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





